# A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

> **NCT06947499** · PHASE2,PHASE3 · RECRUITING · sponsor: **LG Chem** · enrollment: 1186 (estimated)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** LBVD
- **BIOLOGICAL:** Pentavalent vaccine and Inactivated Polio vaccine

## Key facts

- **NCT ID:** NCT06947499
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 1186 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06947499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06947499, "A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06947499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*